

## Article Review

### *On the novel coronavirus (COVID-19): a global pandemic*

James Louis-Jean<sup>1a\*</sup>, Magdonald Aime<sup>2b</sup>

<sup>1</sup> Graduate School, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, United State of America

<sup>2</sup> School of Science, Florida Southwestern State College, 8099 College Pkwy, Fort Myers, FL 33919, United State of America

<sup>a</sup>E-mail address: [louisjea@unlv.nevada.edu](mailto:louisjea@unlv.nevada.edu)

<sup>b</sup>E-mail address: [aime.magdonald@gmail.com](mailto:aime.magdonald@gmail.com)

## HIGHLIGHTS

- COVID-19 has been declared a global health emergency.
- COVID-19 probably transmitted from bats or another host.
- Preventative measures are to be practiced.
- Efforts to develop and validate medications for COVID-19 are underway.

## ARTICLE INFO

### Article history

Received Date: July 27<sup>th</sup>, 2020

Revised Date: August 16<sup>th</sup>, 2020

Accepted Date: August 18<sup>th</sup>, 2020

### Keywords

Zoonosis

COVID-19

Transmission

Respiratory Disease

## ABSTRACT

Coronaviruses (COVs) are viruses transmitted through droplets of sputum from an infected person. Analyses identify COVs as zoonotic pathogens, possibly resulting from human-animal contact at animal markets. They share overlapping genetic characteristics with the avian influenza viruses from China. COVs released from humans through droplets of sputum and may land on various surfaces, which poses exposure risks; as studies have shown the virus can exist intact for a relatively long period of time (several days). The recent highly pathogenic COVs outbreak (COVID-19) emerged in Wuhan, China in 2019, include Severe Acute Respiratory Syndrome (SARs-COV). This highly transmittable disease causes pneumonia and other severe respiratory illnesses similar to SARS and MERS; it has a global mortality rate of about 6.13%. The virus has rapidly become a global pandemic, causing major global issues, including health, economic, and age-preference, among other issues. This text summarizes the nature of the emerging COVID-19 global pandemic while analyzing several factors concerning the etiology of the virus. This is done in an urgent effort to educate and provide relevant information about the virus.

[This is an open-access article under the CC-BY-SA license.](#)



### \*Corresponding Author:

James Louis-Jean

Affiliation: University of Nevada Las Vegas

E-mail: [louisjea@unlv.nevada.edu](mailto:louisjea@unlv.nevada.edu)



## 1. INTRODUCTION

Coronaviruses (COVs) belong to the Coronavirinae subfamily. COVs are single, positive stranded RNA viruses with genome ranging from 26 to 32 kilobases (kbs) in length. Corona means crown. The name, coronavirus, is derived from the appearance of the virion <sup>1,2</sup> which has a crown-like shape with spikes on the outer surface ([Figure 1](#)). Divided into low pathogenic (LP-COVs) and highly pathogenic (HP-COVs), six COVs are known to cause human diseases. LP-COVs are responsible for 10-30% of upper respiratory tract infections and caused minor respiratory diseases. Meanwhile, HP-COVs, which include Severe Acute Respiratory Syndrome (SARS-COV) and Middle East Respiratory Syndrome (MERS-COV), caused fatal pneumonia and infected lower respiratory airways. In 2002, SARS-COV appeared in China, infected 8,098 people, and caused 774 deaths.<sup>3</sup> This resulted in approximately a 9.6% mortality rate before it was controlled in 2003. The MERS-COV first appeared in Saudi Arabia; then, it surfaced in 26 other countries, and caused 2,494 reported cases. With 858 recorded deaths since 2012, MERS-COV had a 34.4% mortality rate.<sup>4</sup> Recently, a novel  $\beta$ -coronavirus (COVID-19) is shown to be highly transmittable and shares SARS-COV-like illness. Initial investigations showed that the virus emerged in Wuhan City, Hubei province in China ([Table 1](#)) in December 2019. As health officials were unable to contain the virus, it rapidly spread to all provinces in China and subsequently to multiple countries and territories ([Figure 2](#)). In late January 2020, the World Health Organization (WHO) declared the virus as a global pandemic.<sup>5</sup>




Figure 1. Microscopic illustration of the COVID-19 virion showing the spike ornaments on the outer surface.<sup>1,2</sup>

Many reports suggested that exposure to COVID-19 came from the Wuhan Seafood Market where wild animals are sold. Wild animals, such as bats, raccoons, snakes, bamboo rats, pangolins, and others, are suggested to be the original source of COVID-19. An intermediate source of origin and transfer to humans is not yet known. Altogether, these COVs are of serious concern to public health.<sup>6</sup> They lead to respiratory tract infections, resulting in pulmonary failure and fatality. In the case of COVID-19, the virus can survive and remain infectious for 2 hours to 9 days in various type of materials.<sup>7,8</sup> With an incubation period of 2-14 days after exposure (infection),<sup>9,10</sup> everyone is prone to the virus, while elderly individuals are more susceptible to experience severe illnesses, including death. Certain individuals are asymptomatic; they, along with individuals in which the virus is in the incubation period, are reported as the primary sources of infection and transmission. Transmission (direct and indirect)<sup>8,11</sup> can occur in various ways. This includes mucus and respiratory droplets from coughing and sneezing, which can all be suspended in air and on surfaces.

Table 1. A tabular comparison of coronaviruses outbreak outlying potential reservoirs, origins, and global data

	SARs-COV <sup>3</sup>	MERS-COV <sup>4</sup>	COVID-19 <sup>12</sup>
Infected	8,098	2,494	6,057,853
Deaths	774	858	371,166
Mortality rate (%)	9.60	34.4	6.13
Potential Reservoirs	Bats; Civet cats	Dromedary camels	Bats; Pangolin
Date	Nov. 2002-July 2003	Sept. 2012-Nov. 2019	Dec. 2019-
Origin	Guangdong, China	Saudi Arabia	Wuhan, China
Affected countries	26	27	<120

All data presented in this text were collected from covidgraph.com and WHO Situation Report-133.<sup>12</sup> At the time of this writing, COVID-19, with a mortality rate of 6.13% – became a global pandemic affecting 6,057,853 individuals in more than 120 countries and territories ([Figure 2](#)). Currently, the United States (USA) has become the new epicenter of the virus with a mortality rate of about 5.48%.




Figure 2. Geographical spread of COVID-19 showing reported cases as of 1 June 2020.<sup>12</sup> For more details, see [WHO COVID-19 Situation Report–133](#).

Among all reported case-fatality, New York, New Jersey, Illinois, California, and Massachusetts represent the top five states with the most fatalities. Altogether, the data shows that elderly individuals have a higher chance of infection. The mortality rate of COVID-19 (17-38%) is higher in elderly individuals with chronic diseases. Analyzing the data from New York state ([Figure 3](#)), the number of reported cases reached 375,133 and the death toll reached 24,133. Male represents 51.6% of the total cases while female represents 48.4%, however the death toll is much higher among male (60.9% death) compared to female (39.1%). Further analysis based on age groups shows the median infected age is 51 years old while individuals >75 are the most affected and vulnerable to COVID-19. Given the nature of the virus – highly contagious – it is important to protect these individuals from the virus by limiting direct interactions with and follow proper guidelines given by health officials. Currently, there are no available drug medications or vaccines to combat this pandemic. As transmission can occur among all age groups, the need to understand the nature of COVID-19 and its characteristics are critical in response to this global outbreak.




Figure 3. COVID-19 reported cases, deaths and lethality among various age groups in New York, USA.

## 2. REVIEW METHOD

All data presented in this text were collected using online resources from covidgraph.com, WHO Situation Reports, and U.S. Center for Disease Control and Prevention. A number of journal articles, news reports and papers available online were also used for sourcing information. All materials used for this publication are published in English. Searches were restricted to focus mainly on SARS-CoV-2, COVID-19, and a few articles searched with the keyword “coronavirus”. All data are properly cited throughout this publication. Knowing that data and information periodically are being made available, readers are encouraged to remain updated with more recent data and information following WHO, CDC, and public health officers.

## 3. RESULTS AND DISCUSSION

### Zoonotic Pathogens

In light of zoonosis, a large number of diseases are due to human-animal contacts, causing local and global epidemic. A selected number of zoonotic diseases are briefly discussed in this text to further evaluate the consequences of zoonosis pathogens. Human-animal contact includes hunting, slaughtering, selling and cooking which pose a great risk of infection to a number of viruses— not only COVs. The handling and processing of animals –including wild animals, opens the door for more deadly pathogens that these animals may harbor. A chain of transmission can occur from human-animal contact and human-human transmission can follow. This is the case of many epidemics, including the avian influenza virus (i.e., H1N1) and numerous COVs (i.e., SARS, MERS). To minimize such epidemics, many researchers suggested not to aggregate various animal species, mammals, and birds in relatively closed environment (i.e., meat markets).<sup>13,14,15</sup>

The zoonotic origin of COVID-19 shares overlapping etiological characteristics with Ebola, as they are both transmitted from animal to human. Following recent studies, the full-length genome of COVID-19 was reported.<sup>10</sup> Its genome and spike glycoprotein showed 96.11% and 92.86% identity to *Rhinolophus affinis* bat coronavirus (BTA-COV) in Wuhan, respectively.<sup>16,17</sup> Bats, also known as flittermouse, with over 1,200 species, comprise about 20% of all mammalian species. They are classified under the order of *Chiroptera* and are found all across the world but Antarctica.<sup>18</sup> It is of interest to note that all continents except Antarctica have shown the presence of COVID-19.<sup>19</sup>

Bats are nocturnal. They can either be insectivores (insect-eater) or frugivores (fruit-eater), whereas other bats (i.e., vampire bats) practice hematophagia (feeding on blood). Surprisingly, bats provide numerous benefits to humans. For instance, their wastes, guano, are collected and used as fertilizer, since guano contains high levels of essential nutrients (nitrogen, phosphate and potassium) for plant growth. In addition, bats are a food source across Asia. However, they are natural reservoirs of various zoonotic pathogens.<sup>20</sup> Nearly 200 coronaviruses are identified

in various bats species.<sup>21</sup> Many studies suggested that bats are a common reservoir for SARs-COV<sup>22</sup>; and the main bat reservoirs were identified in 2003.<sup>23</sup> Various bats species (i.e., *Taphozous perforatus*, *Rhinopoma hardwickii* and *Pipistrellus kuhlii*) are suggested to be the source of MERS-COV.<sup>24</sup> While not yet confirmed, studies suggest that the COVID-19 global outbreak was transmitted from bats to humans. This might occur directly or indirectly via an unknown, intermediate vector.<sup>25,26</sup> While more studies are needed for confirmation, a recent study showed Pangolin (armored anteater) as the intermediate host of COVID-19 virus.<sup>27,28,29</sup> Other studies suggested fish as the potential reservoir of infection from human-animal contact. Altogether, these studies demonstrated human-human transmission of COVID-19 through droplets from direct or indirect contact.<sup>8,30,31</sup> Developing tests at hospital settings showed that the virus is nosocomial, affecting 41% of patients based on incidence and transmission from asymptomatic carriers.<sup>31,32,33,34,35,36,37</sup>

Previously, the Asian palm civet cat (*Paradoxurus hermaphroditus*), a member of the *Viverridae* group, was reported as the reservoirs of SARs-COV from a wild animal market in Guangzhou, China.<sup>38,39,40</sup> The successful identification of this reservoir was pivotal in controlling the virus while suspending all trades of civet cats.<sup>41</sup> Therefore, the need to identify the reservoirs of the emerging COVID-19 outbreak is needed in order to take significant control of the disease and minimize mortality rate.

MERS-COV also has zoonotic origin. Numerous animals and birds were originally tested to identify MERS-COV's actual reservoirs. Results indicated dromedary camels as the actual reservoir (Table 1). Poultry markets in China were tested as the reservoirs for various type of influenza viruses. Learning from various studies concerning COVs and avian influenza, the authors suggested the following measured below in order to combat the virus and identify its reservoir. First, researchers should conduct serological testing of all animals sold at the Wuhan market prior to the widespread disease. This could provide information about the reservoirs and identify if other animals exposed to the virus have developed antibodies against COVID-19. Next, there is a need to investigate the seroconversion from any exposed animals. This is to confer protective immunity against the virus.

## Preventative Measures

To decrease the global effect of COVID-19, government agencies, public health officials, and infection controls personnel need to urgently assess the nature of the virus while providing relevant information to the public. From previous experiences associated to MERS and SARs-COV, the World Health Organization (WHO) has been very critical in responding and recommending infection control interventions. This greatly helps to reduce risk of transmissions which include avoiding contact with affected individuals and wild animals, taking protective measures, and frequent handwashing. The WHO along with the US Centers for Disease Control and Prevention (CDC) have shared many preventative actions to minimize the risk of infection.<sup>42,43</sup> This includes various measures such as social distancing to slow down the rate of transmission (maintain 6 feet, 2 meters, away from each other), sneezing in clothing or disposable tissues, practicing cough etiquette (cover coughs), frequently decontaminating surfaces (i.e., door handles etc.), sheltering-in-place if required, and self-quarantining following domestic and international travels. This is in addition to not kissing (or other intimate social interactions), hugging, or handshaking. In consideration of these measures and the nature of the virus, many businesses are forced to be nonoperational, thus leading to global economic disaster, as the stock market has thus far shown.<sup>44</sup> These efforts are made to reduce the global impact of the virus, allow healthcare administrators and public health to better characterize the nature of the virus. This could greatly afford researchers to develop vaccines, therapeutics, and diagnostics measures in response to the virus in a timely manner. Health officials should constantly engage in circulating information, guidance and clarifying misinformation to the public. While the internet remains as



the major source to relate and spread information, the public should be aware of fake news circulating the internet. The authors recommend individuals to follow credible sources for information (i.e., CDC, WHO, etc.).

### Potential Treatments

Viruses bind to host receptors on target cell surface to generate infection. A recent study showed SARs-COV-2 (known as COVID-19) and SARs-COV use angiotensin-converting enzyme A (ACE-2) to gain entry into the cells.<sup>45</sup> ACE-2 can affect many tissues and organs in the human body since it is present in human's epithelia and small intestine including liver, lung, stomach, ileum, colon, and kidney.<sup>46</sup> This implies that coronaviruses can infect multiple organs (gastrointestinal and upper respiratory tracts). Identifying possible routes of COVID-19 infection could significantly have an impact on treatment of the virus. In this context, researchers have recently reported that the main target cell of COVID-19, AT2 cell is shown to express relatively low levels of ACE-2 in the lung.<sup>45,47,48,49</sup> This implies that COVID-19 may rely on co-receptors or other protein membranes to integrate into cell membrane, deposit its nuclear material, have that nuclear material integrated into host receptors on target cell surface, and have the host cell reproduce the viral particles until that host cell is dead and other cells are infected.<sup>50</sup> This is facilitated through the transmembrane protease serine 2 (TMPRSS2) for priming, where the virus is activated.<sup>51</sup> In this context, inhibition of TMPRSS2 could block cell entry by COVID-19, reduce the virus replication, and present a possible therapeutic pathways.

Currently, there is no effective treatment for COVID-19 and other COVs (i.e., MERS-COV); this is a significant obstacles facing the world. In the absence of known vaccines or medications, researchers are engaged in ongoing efforts to develop and validate medications to combat COVID-19 global pandemic. A number of vaccine candidates (~120) are now in clinical trials; and others are under testing. At the same time, researchers have focused on repurposing many drugs and traditional herbal medicines to combat the most severe cases of infection. Drug repurposing relies on the investigation of existing drugs for new therapeutic purposes.<sup>52,53</sup> This provides an effective way to rapidly recognize drugs with known side effects to be used while new drugs are under preparations.

Repurposing drugs such as hydroxychloroquine/chloroquine, used to prevent and treat malaria, in addition to autoimmune disease (rheumatoid arthritis, lupus, and porphyria cutanea tarda), is found to inhibit the replication of many DNA and RNA viruses— as in many coronaviruses.<sup>54,55,56</sup> The China National Center for Biotechnology Development (CNCBD) reported that infected patients (about 100) treated with chloroquine have showed improvements in their lung and decline in fever. In addition, these patients rapidly recovered when compared to the control groups. With the promising results from these studies, the Chinese Government proposed chloroquine as the front line drug treatment for the severe COVID-19 outbreak.<sup>57,58,59,60</sup> Ten clinical trials are underway to investigate the chloroquine as an anti-COVID-19 therapy.<sup>61</sup> While the drug is well known,<sup>62,63</sup> adverse side effects from COVID-19 patients treated with chloroquine need to be investigated. In the meantime, chloroquine remains as the available drug to fight the disease in China and other countries are suggested to use it. However, ongoing researches have shown that the use of hydroxychloroquine/chloroquine might be detrimental to COVID-19 infected patients.

In addition to chloroquine, teicoplanin can be an alternative drug for the treatment of COVID-19.<sup>64</sup> Teicoplanin has been found to significantly inhibit cellular entry of Ebola virus, SARs-COV and MERS-COV.<sup>65</sup> This antibiotic drug also shows efficacy against Staphylococcal infections, hepatitis C virus, HIV virus and influenza virus.<sup>65,66</sup> Further investigations are needed for the inclusion of teicoplanin as a potential repurposing drug for the treatment of COVID-19 global outbreak.

Remdesivir, a purine nucleoside analogue, is a broad-spectrum antiviral medicine developed by Gilead Sciences; it was previously used to treat Ebola and Marburg virus infection.<sup>67</sup> The medication was found to show antiviral activity against other single-stranded RNA viruses, such as respiratory syncytial virus and COVs.<sup>68,69,70</sup> Remdesivir is currently in clinical trials in Nebraska and China on hospitalized patients with COVID-19 to evaluate its safety and efficacy. Although this medication has been administered to patients, there is no available data on whether it can improve clinical outcomes.

Interferon Alfa-2B is an antiviral medicine used to treat hepatitis B and C, certain types of cancer, and genital warts. The medication was developed in Cuba; it is currently in clinical trials to treat COVID-19 patients in China, where the virus originally emerged.<sup>71,72</sup> Due to the absence of a general treatment, repurposing drugs such as those described above are suggested as potential treatments for patients infected with COVID-19, while researchers are investigating actual treatments.

Table 2. Medicinal Plants with Therapeutic Histories

Plants	Bioactive/antiviral compounds	Therapeutics
<i>Zingiber officinale</i>	Gingerol; Shogaols	Human respiratory syncytial virus
<i>Allium sativum</i>	Allicin	Influenza virus
<i>Euphorbia hirta</i>	Afzelin; Quercetin; Myricitrin; Rutin; Garlic acid; Caffeic acid	Asthma conjunctivitis
<i>Curcuma longa</i>	Curcumin	Dengue virus; Hepatitis C virus; Zika virus, Chikungunya virus
<i>Olea europaea</i>	Oleuropin	Herpes; mononucleosis; hepatitis virus; rotavirus; bovine rhinovirus; canine parvovirus; feline leukaemia virus; Respiratory syncytial virus; Parainfluenza type 3 virus
<i>Aloe vera</i>	Emodin; Chrysophanol; Aloe-emodin	Human respiratory syncytial virus
<i>Allium Cepa</i>	Quercetin; Isorhamnetin; Kaempferol; Myricetin	Human immunodeficiency virus (HIV); Herpes simplex virus type 1; Poliovirus type 1; Parainfluenza virus type 3; Potato virus
<i>Garcenea Kola</i>	Kolaviron	Influenza virus; Hepatitis; Diarrhea; Laryngitis; Bronchitis; Gonorrhoea; Chest colds; Coughs
<i>Echinacea</i>	Caffeic acid	Colds; Influenza; Lung conditions; Candidiasis; Influenza A virus; Herpes simplex virus; Polio virus

Note: See reference <sup>73</sup> for a comprehensive review

In addition to repurposing drugs, various plants containing bioactive compounds have shown to be effective against previous coronaviruses. These plants include *Zingiber officinale*, *Allium cepa*, *Allium sativum*, *echinacea*, *euphorbia hirta*, *Garcenea kola*, *Curcuma longa*, *Aloe vera* and *olea europaea* (Table 2). The natural compounds from these plants could have potency to inhibit TMPRSS2, thus reducing the virus (COVID-19) replication. Research to better understand the mechanism of these herbal medicines are not yet fully available. However, herbal medicines have been produced in higher demands due to their use against COVID-19 (i.e., Madagascar). Countries such as China, Thailand, Bolivia, Tunisia, India, Haiti, Madagascar, and Nigeria have their respective traditional herbal medicine against the virus.<sup>73,74,75,76,77,78,79</sup> In a study reported by the National Health Commission of the People's Republic of China, of the 74,187 patients treated with traditional herbal medicines, nearly 90% of them have recovered. This further proves the potential use of herbal medicines to fight COVID-19 while given researchers more time to develop potential vaccines.

#### 4. CONCLUSION

The novel coronavirus disease (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARs-COV-2). To date, the virus remains a global health issue, affecting 6,057,853 individuals with 371,166 confirmed deaths (6.13 % mortality rate) in more than 120 countries and territories. This emerging virus continues to cause a public health issue, economic disaster, physiological distress—including discrimination, and limit human activities.<sup>80,81</sup>

While the source of the virus and its immediate host remain controversial, researchers are engaged in ongoing efforts to develop and validate medications to combat the COVID-19 global pandemic. Due to the absence of a general treatment, many repurposing drugs and traditional herbal medicines are suggested as potential treatments for patients infected with COVID-19.

## ACKNOWLEDGMENT

Thanks are due to Ms. Debbie Sanon, Ms. Ruthonce Stvil, and Dr. Rose Mary Stiffin for their contribution and feedback.

## DISCLOSURE STATEMENT

The authors reported no potential conflict of interest.

## FUNDING INFORMATION

This research did not receive any specific grant from public, government, commercial or non-profit funding agencies.

## REFERENCES

1. Powell A. Coronavirus Cases Hit 17,400 and Are Likely to Surge. The Harvard Gazette. 2020. <https://news.harvard.edu/gazette/story/2020/02/as-confirmed-cases-of-coronavirus-surge-path-grows-uncertain/>
2. US Centers for Disease Control and Prevention- Coronavirus Disease 2019. 2020. <https://www.cdc.gov/>
3. Summary of Probable SARS Cases With Onset of Illness From 1 November 2002 to 31 July 2003. World Health Organization. 2003. [www.who.int/csr/sars/country/table2003\\_09\\_23/en](http://www.who.int/csr/sars/country/table2003_09_23/en)
4. Middle East Respiratory Syndrome Coronavirus (MERS-CoV). World Health Organization 2019. <http://applications.emro.who.int/docs/EMRPUB-CSR-241-2019-EN.pdf?ua=1&ua=1&ua=1>
5. Novel Coronavirus (2019-nCoV) Situation Report - 11. World Health Organization. 2020. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4)
6. Louis-Jean J, Cenat K, Sanon D, Stvil R. Coronavirus (COVID-19) in Haiti: A Call for Action. *J Community Heal.* 2020;45(3):437-439. [doi:10.1007/s10900-020-00825-9](https://doi.org/10.1007/s10900-020-00825-9).
7. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect.* 2020;104(3):246-251. [doi:10.1016/j.jhin.2020.01.022](https://doi.org/10.1016/j.jhin.2020.01.022).
8. Enyoh CE, Verla AW, Qingyue W, et al. Indirect Exposure to Novel Coronavirus (SARS-CoV-2): An Overview of Current Knowledge. *J Teknol Lab.* 2020;9(1):67-77. [doi:10.29238/teknolabjournal.v9i1.227](https://doi.org/10.29238/teknolabjournal.v9i1.227).
9. Linton NM, Kobayashi T, Yang Y, et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med.* 2020;9(2):538. [doi:10.3390/jcm9020538](https://doi.org/10.3390/jcm9020538).
10. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727-733. [doi:10.1056/NEJMoa2001017](https://doi.org/10.1056/NEJMoa2001017).
11. Enyoh CE, Verla AW, Verla EN. Novel Coronavirus (SARS-CoV-2) and Airborne Microplastics. *medRxiv.* April 2020. [doi:10.5281/ZENODO.3738452](https://doi.org/10.5281/ZENODO.3738452).
12. Coronavirus Disease 2019 (COVID-19) Situation Report – 133. World Health Organization.
13. Leung YHC, Lau EHY, Zhang LJ, Guan Y, Cowling BJ, Peiris JSM. Avian Influenza and Ban on Overnight Poultry Storage in Live Poultry Markets, Hong Kong. *Emerg Infect Dis.*



- 2012;18(8):1339-1341. [doi:10.3201/eid1808.111879](https://doi.org/10.3201/eid1808.111879).
14. Cheng KL, Wu J, Shen WL, et al. Avian Influenza Virus Detection Rates in Poultry and Environment at Live Poultry Markets, Guangdong, China. *Emerg Infect Dis*. 2020;26(3):591-595. [doi:10.3201/eid2603.190888](https://doi.org/10.3201/eid2603.190888).
  15. Yu H, Wu JT, Cowling BJ, et al. Effect of Closure of Live Poultry Markets on Poultry-to-Person Transmission of Avian Influenza A H7N9 Virus: An Ecological Study. *Lancet*. 2014;383(9916):541-548. [doi:10.1016/S0140-6736\(13\)61904-2](https://doi.org/10.1016/S0140-6736(13)61904-2).
  16. Lau SKP, Woo PCY, Li KSM, et al. Severe Acute Respiratory Syndrome Coronavirus-Like Virus in Chinese Horseshoe Bats. *Proc Natl Acad Sci*. 2005;102(39):14040-14045. [doi:10.1073/pnas.0506735102](https://doi.org/10.1073/pnas.0506735102).
  17. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Tsiodras S. Full-Genome Evolutionary Analysis of the Novel Corona Virus (2019-nCoV) Rejects the Hypothesis of Emergence as a Result of a Recent Recombination Event. *Infect Genet Evol*. 2020. [doi:10.1101/2020.01.26.920249](https://doi.org/10.1101/2020.01.26.920249).
  18. Teeling EC, Jones G, Rossiter SJ. Phylogeny, Genes, and Hearing: Implications for the Evolution of Echolocation in Bats. In: Fenton MB, Grinnell AD, Popper AN, Fay RR, eds. *Bat Bioacoustics*. New York, NY: Springer; 2016:25-54. [doi:10.1007/978-1-4939-3527-7\\_2](https://doi.org/10.1007/978-1-4939-3527-7_2).
  19. Taylor A, Pitrelli S. One Continent Remains Untouched by the Coronavirus: Antarctica. *The Washington Post*. 2020. <https://www.washingtonpost.com/world/2020/03/24/one-continent-remains-untouched-by-coronavirus-antarctica/>
  20. Wong S, Lau S, Woo P, Yuen K-Y. Bats as a Continuing Source of Emerging Infections in Humans. *Rev Med Virol*. 2007;17(2):67-91. [doi:10.1002/rmv.520](https://doi.org/10.1002/rmv.520).
  21. Chen L, Liu B, Yang J, Jin Q. DBatVir: The Database of Bat-Associated Viruses. *Database (Oxford)*. 2014;2014:bau021. [doi:10.1093/database/bau021](https://doi.org/10.1093/database/bau021).
  22. Fan Y, Zhao K, Shi Z-L, Zhou P. Bat Coronaviruses in China. *Viruses*. 2019;11(3):210. [doi:10.3390/v11030210](https://doi.org/10.3390/v11030210).
  23. Guan Y. Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China. *Science (80-)*. 2003;302(5643):276-278. [doi:10.1126/science.1087139](https://doi.org/10.1126/science.1087139).
  24. Lau SKP, Zhang L, Luk HKH, et al. Receptor Usage of a Novel Bat Lineage C Betacoronavirus Reveals Evolution of Middle East Respiratory Syndrome-Related Coronavirus Spike Proteins for Human Dipeptidyl Peptidase 4 Binding. *J Infect Dis*. 2018;218(2):197-207. [doi:10.1093/infdis/jiy018](https://doi.org/10.1093/infdis/jiy018).
  25. Salata C, Calistri A, Parolin C, Palù G. Coronaviruses: A Paradigm of New Emerging Zoonotic Diseases. *Pathog Dis*. 2019;77(9). [doi:10.1093/femspd/ftaa006](https://doi.org/10.1093/femspd/ftaa006).
  26. York A. Novel Coronavirus Takes Flight from Bats? *Nat Rev Microbiol*. 2020;18(4):191-191. [doi:10.1038/s41579-020-0336-9](https://doi.org/10.1038/s41579-020-0336-9).
  27. Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Curr Biol*. March 2020. [doi:10.1016/j.cub.2020.03.022](https://doi.org/10.1016/j.cub.2020.03.022).
  28. Lam TT-Y, Shum MH-H, Zhu H-C, et al. Identification of 2019-nCoV Related Coronaviruses in Malayan Pangolins in Southern China. *BioRxiv*. 2020. [doi:10.1101/2020.02.13.945485](https://doi.org/10.1101/2020.02.13.945485).
  29. Tang X, Wu C, Li X, et al. On the Origin and Continuing Evolution of SARS-CoV-2. *Nat Sci Rev*. March 2020. [doi:10.1093/nsr/nwaa036](https://doi.org/10.1093/nsr/nwaa036).
  30. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. January 2020. [doi:10.1056/NEJMoa2001316](https://doi.org/10.1056/NEJMoa2001316).
  31. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061. [doi:10.1001/jama.2020.1585](https://doi.org/10.1001/jama.2020.1585).

32. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. [doi:10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
33. Chang D, Lin M, Wei L, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA*. 2020;323(11):1092-1093. [doi:10.1001/jama.2020.1623](https://doi.org/10.1001/jama.2020.1623).
34. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. *Am J Crit Care Med*. 2020;201(4):7-8. [doi:10.1164/rccm.2014P7](https://doi.org/10.1164/rccm.2014P7).
35. Zhao S, Lin Q, Ran J, et al. Preliminary Estimation of the Basic Reproduction Number of Novel Coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-Driven Analysis in the Early Phase of the Outbreak. *Int J Infect Dis*. 2020;92:214-217. [doi:10.1016/j.ijid.2020.01.050](https://doi.org/10.1016/j.ijid.2020.01.050).
36. Biscayart C, Angeleri P, Lloveras S, Chaves T do SS, Schlagenhauf P, Rodríguez-Morales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI). *Travel Med Infect Dis*. 2020;33(January):101567. [doi:10.1016/j.tmaid.2020.101567](https://doi.org/10.1016/j.tmaid.2020.101567).
37. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment. *N Engl J Med*. 2020;382(8):692-694. [doi:10.1056/NEJMp2000929](https://doi.org/10.1056/NEJMp2000929).
38. Xiao Y, Meng Q, Yin X, et al. Pathological Changes in Masked Palm Civets Experimentally Infected by Severe Acute Respiratory Syndrome (SARS) Coronavirus. *J Comp Pathol*. 2008;138(4):171-179. [doi:10.1016/j.jcpa.2007.12.005](https://doi.org/10.1016/j.jcpa.2007.12.005).
39. Wang M, Yan M, Xu H, et al. SARS-CoV Infection in a Restaurant from Palm Civet. *Emerg Infect Dis*. 2005;11(12):1860-1865. [doi:10.3201/eid1112.041293](https://doi.org/10.3201/eid1112.041293).
40. Xu H-F, Xu R-H, Xu J-G, et al. Study on the Dynamic Prevalence of Serum Antibody Against Severe Acute Respiratory Syndrome Coronavirus in Employees From Wild Animal Market in Guangzhou. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2006;27(11):950-952.
41. Parry J. WHO Queries Culling of Civet Cats. *BMJ*. 2004;328(7432):128. [doi:10.1136/bmj.328.7432.128-b](https://doi.org/10.1136/bmj.328.7432.128-b).
42. Coronavirus Disease 2019 (COVID-19)- How COVID-19 Spreads. US Centers for Disease Control and Prevention. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html>
43. Coronavirus Disease (COVID-19) Advice for the Public. World Health Organization. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public>
44. Evans O. Socio-Economic Impacts of Novel Coronavirus: The policy Solutions. *BizEcons Quarterly, Strides Educ Found*. 2020;7:3-12.
45. Letko M, Marzi A, Munster V. Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Betacoronaviruses. *Nat Microbiol*. February 2020. [doi:10.1038/s41564-020-0688-y](https://doi.org/10.1038/s41564-020-0688-y).
46. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A first Step in Understanding SARS Pathogenesis. *J Pathol*. 2004;203(2):631-637. [doi:10.1002/path.1570](https://doi.org/10.1002/path.1570).
47. Zhou P, Yang X-L, Wang X-G, et al. A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin. *Nature*. 2020;579(7798):270-273. [doi:10.1038/s41586-020-2012-7](https://doi.org/10.1038/s41586-020-2012-7).
48. Zhou P, Yang X-L, Wang X-G, et al. Discovery of a Novel Coronavirus Associated With The Recent Pneumonia Outbreak in Humans and its Potential Bat Origin. *BioRxiv*. 2020. [doi:10.1101/2020.01.22.914952](https://doi.org/10.1101/2020.01.22.914952).

49. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-Cell RNA-seq Data Analysis on the Receptor ACE2 Expression Reveals the Potential Risk of Different Human Organs Vulnerable to 2019-nCoV Infection. *Front Med*. March 2020. [doi:10.1007/s11684-020-0754-0](https://doi.org/10.1007/s11684-020-0754-0).
50. Zhang Z, Zhu Z, Chen W, et al. Cell Membrane Proteins With High N-Glycosylation, High Expression and Multiple Interaction Partners are Preferred by Mammalian Viruses as Receptors. Wren J, ed. *Bioinformatics*. 2019;35(5):723-728. [doi:10.1093/bioinformatics/bty694](https://doi.org/10.1093/bioinformatics/bty694).
51. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. March 2020;181(2):271-280. [doi:10.1016/j.cell.2020.02.052](https://doi.org/10.1016/j.cell.2020.02.052).
52. Sleight SH, Barton CL. Repurposing Strategies for Therapeutics. *Pharmaceut Med*. 2010;24(3):151-159. [doi:10.1007/BF03256811](https://doi.org/10.1007/BF03256811).
53. Ashburn TT, Thor KB. Drug Repositioning: Identifying and Developing New Uses for Existing Drugs. *Nat Rev Drug Discov*. 2004;3(8):673-683. [doi:10.1038/nrd1468](https://doi.org/10.1038/nrd1468).
54. Devaux CA, Rolain J-M, Colson P, Raoult D. New Insights on the Antiviral Effects of Chloroquine Against Coronavirus: What to Expect for COVID-19? *Int J Antimicrob Agents*. March 2020;55(5):105938. [doi:10.1016/j.ijantimicag.2020.105938](https://doi.org/10.1016/j.ijantimicag.2020.105938).
55. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. *Lancet*. 2014;383(9918):723-735. [doi:10.1016/S0140-6736\(13\)60024-0](https://doi.org/10.1016/S0140-6736(13)60024-0).
56. Lee S-J, Silverman E, Bargman JM. The Role of Antimalarial Agents in the Treatment of SLE and Lupus Nephritis. *Nat Rev Nephrol*. 2011;7(12):718-729. [doi:10.1038/nrneph.2011.150](https://doi.org/10.1038/nrneph.2011.150).
57. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020;14(1):72-73. [doi:10.5582/bst.2020.01047](https://doi.org/10.5582/bst.2020.01047).
58. Zhi ZJHHXZ. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia. 2020;43. [doi:10.3760/cma.j.issn.1001-0939.2020.03.009](https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009).
59. Wang M, Cao R, Zhang L, et al. Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro. *Cell Res*. 2020;30(3):269-271. [doi:10.1038/s41422-020-0282-0](https://doi.org/10.1038/s41422-020-0282-0).
60. Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 Novel Coronavirus SARS-CoV-2. *Int J Antimicrob Agents*. 2020;55(3):105923. [doi:10.1016/j.ijantimicag.2020.105923](https://doi.org/10.1016/j.ijantimicag.2020.105923).
61. Harrison C. Coronavirus Puts Drug Repurposing on the Fast Track. *Nat Biotechnol*. February 2020;38(4):379-381. [doi:10.1038/d41587-020-00003-1](https://doi.org/10.1038/d41587-020-00003-1).
62. Winzeler EA. Malaria research in the post-genomic era. *Nature*. 2008;455(7214):751-756. [doi:10.1038/nature07361](https://doi.org/10.1038/nature07361).
63. Parhizgar AR, Tahghighi A. Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review. *Iran J Med Sci*. 2017;42(2):115-128.
64. Zhang J, Ma X, Yu F, et al. Teicoplanin Potently Blocks The Cell Entry of 2019-nCoV. *BioRxiv*. 2020. [doi:10.1101/2020.02.05.935387](https://doi.org/10.1101/2020.02.05.935387).
65. Zhou N, Pan T, Zhang J, et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). *J Biol Chem*. 2016;291(17):9218-9232. [doi:10.1074/jbc.M116.716100](https://doi.org/10.1074/jbc.M116.716100).
66. Colson P, Raoult D. Fighting Viruses With Antibiotics: An Overlooked Path. *Int J Antimicrob Agents*. 2016;48(4):349-352. [doi:10.1016/j.ijantimicag.2016.07.004](https://doi.org/10.1016/j.ijantimicag.2016.07.004).
67. Warren TK, Jordan R, Lo MK, et al. Therapeutic Efficacy of the Small Molecule GS-5734 Against Ebola Virus in Rhesus Monkeys. *Nature*. 2016;531(7594):381-385.

- [doi:10.1038/nature17180](https://doi.org/10.1038/nature17180).
68. Lo MK, Jordan R, Arvey A, et al. GS-5734 and its Parent Nucleoside Analog Inhibit Filo-, Pneumo-, and Paramyxoviruses. *Sci Rep*. 2017;7(1):43395. [doi:10.1038/srep43395](https://doi.org/10.1038/srep43395).
  69. Sheahan TP, Sims AC, Graham RL, et al. Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses. *Sci Transl Med*. 2017;9(396):eaal3653. [doi:10.1126/scitranslmed.aal3653](https://doi.org/10.1126/scitranslmed.aal3653).
  70. Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. Subbarao K, ed. *MBio*. 2018;9(2). [doi:10.1128/mBio.00221-18](https://doi.org/10.1128/mBio.00221-18).
  71. Cuba to Send Doctors and Pharmaceuticals to Nicaragua to Face Coronavirus. Cuba News. 2020. <https://oncubanews.com/en/cuba/cuba-to-send-doctors-and-pharmaceuticals-to-nicaragua-to-face-coronavirus/>
  72. Cuban Drug Used Against Coronavirus in China Available in Panama. MENAFM. 2020. <https://menafn.com/1099841078/Cuban-drug-used-against-coronavirus-in-China-available-in-Panama>
  73. Chiyere IBC, Tochukwu MOD, Enyoh CE, Uju IJM. Potential Plants for Treatment and Management of COVID-19 in Nigeria. *Acad J Chem*. 2020;5(6):69-80. [doi:10.32861/ajc.56.69.80](https://doi.org/10.32861/ajc.56.69.80).
  74. Lemaire S, Vilme M. Armed with Sunflower Tea and Ginger Root, Haitian Mountain People Ready to Treat COVID-19 Symptoms. *Voice of America*. 2020. <https://www.voanews.com/covid-19-pandemic/armed-sunflower-tea-and-ginger-root-haitian-mountain-people-ready-treat-covid-19>
  75. Timoshyna A, Xu L, Ke Z. COVID-19—The Role of Wild Plants in Health Treatment and why Sustainability of their Trade Matters. *Traffic*. 2020. <https://www.traffic.org/news/covid-19-the-role-of-wild-plants-in-health-treatment/>
  76. Covid-19 Fear Fuels Rush for Traditional Herbal Medication. *Bangkok Post*. 2020. <https://www.bangkokpost.com/thailand/general/1880490/covid-19-fear-fuels-rush-for-traditional-herbal-medication>
  77. COVID-19: Boost your Immunity with Dalmia Group's Herbal Capsule. *Econ Times Panache*. 2020. <https://economictimes.indiatimes.com/magazines/panache/covid-19-boost-your-immunity-with-dalmia-groups-herbal-capsule/articleshow/74684873.cms>
  78. *New York Times*. 2020. <https://www.nytimes.com/reuters/2020/03/21/world/americas/21reuters-health-coronavirus-bolivia-tradition.html>
  79. Madagascar "Anti-Virus Brews" Sell Like Hot Cakes in Local Markets. *News 24*. 2020. <https://www.news24.com/news24/africa/news/madagascar-anti-virus-brews-sell-like-hot-cakes-in-local-markets-20200326>
  80. Louis-Jean J, Cenat K. Beyond the Face-to-Face Learning: A Contextual Analysis. *Pedagog Res*. 2020;5(4). [doi:10.29333/pr/8466](https://doi.org/10.29333/pr/8466).
  81. Louis-Jean J, Cenat K, Njoku C V., Angelo J, Sanon D. Coronavirus (COVID-19) and Racial Disparities: A Perspective Analysis. *J Racial Ethn Heal Disparities*. 2020. <https://www.springer.com/journal/40615>

## SHORT BIOGRAPHY

Orcid: 0000-0002-7711-0967